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Structured abstract: 247 words (max 250 words) 
Background: The aim of this study was to compare long-term thromboembolic risk in infection-
related and non-infection-related atrial fibrillation (AF). 
Methods: Using Danish nationwide registries, we identified patients with first-time AF from 1996 –
2015 and performed a retrospective cohort study. We did a 1:1 match (upon sex, age, calendar year, 
and oral anticoagulation (OAC) status at the beginning of follow-up) of patients with infection-
related (concurrent discharge diagnosis code for infection) and non-infection-related AF. Long-term 
outcomes were examined using multivariable Cox regression analyses.  
Results: Our study population comprised 48,644 patients equally distributed on infection-related 
and non-infection-related AF. In both groups, those initiated on OAC therapy were younger than 
those not initiated on OAC therapy (median age 77 years, interquartile range 69-83 versus median 
age 79 years, interquartile range 71-86). During the 1st year of follow up, infection-related AF was 
associated with an increased risk of thromboembolic events compared with non-infection-related 
AF: adjusted hazard ratio (HR) 1.44 (95% confidence interval (CI) 1.16-1.78) for those initiated on 
OAC therapy and HR 1.17 (95% CI 1.06-1.28) for those not initiated on OAC therapy. In both 
groups, OAC therapy was associated with better outcomes than no OAC therapy (HR of 
thromboembolic events 0.75 (95% CI 0.68- 0.83) and HR 0.70 (95% CI 0.63- 0.78) for patients 
with infection-related and non-infection-related AF, respectively).  
Conclusion: Infection was associated with an increased thromboembolic risk in patients with first-
time AF. OAC therapy was associated with a similar risk-reduction in AF patients with and without 
a concurrent infection. 
Key words: Stroke, atrial fibrillation, infection, longitudinal population-based cohorts, 
anticoagulation therapy 
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Highlights  
 Infection-related and non-infection-related AF was at least equal in thromboembolic risk  
 Infection-related AF had lower rates of AF re-hospitalizations 
 OAC therapy was associated with a lower thromboembolic risk in infection-related AF 
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Introduction 
Atrial fibrillation (AF) occurring secondary to infection is common, yet little data exist on long-
term outcomes for patients in this setting.1 European and American guidelines from 2011 stated 
that AF occurring secondary to another precipitant (e.g. pneumonia, myocardial infarction, 
pericarditis etc.) usually will terminate without recurrence.2 This recommendation was, however, 
retracted in current guidelines, where no such recommendations regarding oral anticoagulation 
(OAC) therapy for patients with AF in this setting exist.3, 4 Further, the randomized controlled 
trials regarding OAC therapy as stroke prophylaxis in AF patients excluded patients with AF due to 
reversible conditions.5–9 When it comes to thromboembolic risk, it is unknown whether AF 
secondary to reversible precipitants differs from AF in general. Recently, Lubitz et al. found a 42% 
five-years recurrence rate of AF among patients with first-detected AF at the same time as a 
reversible secondary precipitant.1 Since AF without a precipitating cause is associated with a high 
risk of thromboembolism, and since this thromboembolic risk is unknown when a precipitating 
cause is present, it is important for clinical decision making to seek further knowledge of the risk of 
thromboembolism when a precipitating cause of AF is present with and without the use of OAC 
therapy.4, 10 
We compared the long-term risk of thromboembolic events, AF re-hospitalization, and death among 
patients presenting with first-time AF with and without a concurrent infection.  
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Methods 
Data sources 
We linked data on an individual level across four nationwide registries. The Danish Civil 
Registration System holds information about date of birth and death, sex, and emigration.11 The 
Danish national patient registry holds information about all hospital contacts and includes diagnosis 
codes and dates of hospital visits.12 Diagnoses are registered in terms of the International 
Classification of Diseases (ICD) system (ICD-8 until 1994, ICD-10 thereafter). The Danish 
Register of Causes of Death 13 holds information about causes of death and the Danish National 
Registry of Medicinal Statistics holds information about all filled prescriptions in Denmark.14 
 
Infection-related AF 
Among all Danish residents, patients with first-time F and infection during the same hospital 
admission from January 1, 1996 to September 30, 2015 were defined as having infection-related 
AF. The very young and old patients (<18 years or >100 years), those who had emigrated before the 
inclusion, and those with valvular AF were excluded (Figure 1). To ensure exclusion of patients 
with previously diagnosed AF (e.g. at a general practitioner), we excluded those treated with OAC 
therapy 100 days prior to their AF hospital admission and patients treated with antiarrhythmic and 
rate-controlling drugs at any time before their AF hospital admission. See Online Table 1 for 
specification of diagnosis codes and anatomical therapeutic chemical codes.  
 
Non-infection-related AF 
All Danish residents admitted with AF for the first time from January 1, 1996 to September 30, 
2015 without a concurrent infection were identified. We applied the same exclusion criteria as for 
the group with infection-related AF (Figure 1).  
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Study population 
To exclude the most fragile patients, those who had a thromboembolic event or died during a 
blanking period of 14 days from discharge to a defined index date were excluded. Initiation of OAC 
therapy was assessed during this blanking period. Among those available for follow up at the index 
date (alive and not emigrated), we did a one to one match by incidence density sampling according 
to age, sex, calendar year, and OAC status at the index date of AF patients with and without a 
concurrent infection. We used a previously described function to perform the match.15 
 
Long-term outcomes 
The outcomes of interest included thromboembolic events (ischemic stroke, transient ischemic 
attack, and systemic thromboembolism), bleeding events, AF re-hospitalization, and death (of any 
cause). AF re-hospitalization only included those with AF as the primary diagnosis. Patients were 
followed from the index date and until an event, death, emigration, end of study period (December 
31, 2015), or five years after the index date, whichever came first. AF and ischemic stroke have 
been validated in the Danish registries with a positive predictive value of 93% and 97%, 
respectively.16, 17 There exist no validation study on infection-related AF. 
 
Statistics 
Patient characteristics were presented for AF patients with and without a concurrent infection 
according to OAC therapy at the index date and including diagnoses given during the AF 
hospitalization. Cumulative incidences of long-term outcomes (taking into account the competing 
risk of death) were calculated using the Aalen Johansen estimator. Differences across groups were 
tested by using the Log Rank and the Gray’s test. Crude and adjusted hazard ratios (HR) (adjusted 
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for alcohol abuse, cancer, chronic kidney disease, diabetes, heart failure, hypertension, ischemic 
heart disease, peripheral artery disease, bleeding events, prior thromboembolic events, thyroid 
disease, and antiarrhythmic and rate-controlling therapy in the analyses on thromboembolic events 
and further chronic obstructive pulmonary disease and liver disease for the analysis on death) were 
calculated by Cox regression models comparing the risk of long-term outcomes in AF patients with 
and without a concurrent infection using unconditional analyses comparing cases and controls 
within each matching strata and shown by OAC therapy at the index date. We tested for clinically 
relevant interactions including age, calendar year, and several comorbidities. Since the assumption 
of proportional hazards was not met in the analyses on thromboembolic events, these analyses were 
stratified in two time periods. OAC treatment effect was assessed by multivariable Cox regression 
models including thromboembolic events and death as endpoints. A two-sided P-value <0.05 was 
considered statistically significant. All statistical analyses were performed by A.G. in SAS 
statistical software version 9.4 and R Studio.18 
 
Other analyses 
To account for potential changes in OAC therapy status over time, we adjusted for changes in 
therapy in a sensitivity analysis. To address the validity of the infection diagnosis, we performed 
analyses on long-term outcomes only including patients with a c-reactive protein level >49 mg/L in 
the infection-related AF group. Also, long-term outcomes were examined in a non-matched 
population, including all patients available for matching (see Figure 1). See Supplementary material 
for further specifications. In a sub analysis, we stratified the infection-related AF group into the 
following groups according to type of infection: pneumonia, urinary tract infection, gastrointestinal 
infection, sepsis, and other infections. Long-term thromboembolic risk was assessed for each sub 
group and compared with non-infection-related AF. To test, whether underlying heart disease or AF 
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risk factors influenced the results, we did sensitivity analyses on different subgroups of the patients 
with infection-related defined from underlying ischemic heart disease, heart failure (incl. 
cardiomyopathies), hypertension, and diabetes. 
 
Ethics 
Approval from the Research Ethics Committee System is not required in retrospective registry-
based studies in Denmark. The Danish Data Protection Agency approved use of data for this study 
(ret.no: 2007-58-0015 / GEH-2014-013 I-Suite no: 02731).  
 
Results 
Study population 
The patient selection is depicted in Figure 1. After exclusions, 24,607 patients with infection-related 
AF and 68,746 patients with non-infection-related AF were available for matching. Patients with 
infection-related AF were less likely to receive OAC therapy (24.3% versus 41.7%), they were 
older, had more comorbid illness, and higher risk scores for stroke and bleeding than patients with 
non-infection-related AF (Online Table 2).  
After matching, the study population comprised 24,607 patients with infection-related AF and 
24,607 patients with non-infection-related AF. Infections in the respiratory system were the most 
common infections (online Table 3). Table 1 shows the baseline characteristics of the matched 
study population. In general, the patients with infection-related AF had more comorbidities than 
patients with non-infection-related AF, and in both groups, patients initiated on OAC therapy had 
less comorbidity compared with patients not initiated on OAC therapy.  
 
Treatment over time 
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Equal proportions of patients with infection-related and non-infection-related AF discontinued 
OAC therapy over time (Online Figure 1A). Of those on no OAC therapy at the index date, more 
patients with non-infection-related AF than infection-related AF initiated OAC therapy over time 
(Online Figure 1B). By six months from the index date, 50.0% and 46.1% of patients with 
infection-related and non-infection-related AF, respectively, were in antiarrhythmic or rate-
controlling therapy.  
 
Long-term outcomes 
The median follow-up time from the index date to death, study end (5 years after the index date or 
December 31, 2015), or emigration was 2.5 years (IQR 0.7 –5.0) for patients with infection-related 
AF and 3.6 years (IQR 1.3 –5.0) for patients with non-infection-related AF. During follow-up, 
14.6% of the patients with infection-related AF compared with 27.4% of the patients with non-
infection-related AF had a re-admission with AF (adjusted HR 0.60, 95% confidence interval (CI) 
0.56–0.64 for patients on OAC therapy at the index date and adjusted HR 0.51, 95% CI 0.48-0.54 
for patients on no OAC therapy at the index date). The cumulative incidences of thromboembolic 
events and death in AF patients with and without a concurrent infection according to OAC therapy 
at the index date are depicted in Figure 2 (A: thromboembolic events during the 1st year from the 
index date, B: thromboembolic events one to five years from the index date, C: Kaplan Meier curve 
for death). Figure 3 illustrates incidence rates and crude and adjusted HRs of long-term outcomes in 
patients with infection-related AF compared with patients with non-infection-related AF according 
to OAC therapy status at the index date. During the 1st year from the index date, infection-related 
AF was associated with an increased risk of thromboembolic events compared with non-infection-
related AF. After one year, this risk decreased, and became comparable to the thromboembolic risk 
in non-infection-related AF. No differences were found in bleeding risk across the two patient 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
11 
 
groups when initiated on OAC therapy at the index date. For those not initiated on OAC therapy, 
infection-related AF was associated with an increased risk of bleeding events. Infection-related AF 
was associated with a higher risk of death than non-infection-related AF. OAC therapy vs. no OAC 
therapy was associated with a lower the risk of thromboembolic events and death and a higher 
bleeding risk for both infection-related and non-infection related AF patients (Figure 4).  
 
Other analyses 
Adjustments for OAC therapy as a time-dependent variable did not change the results on 
thromboembolic events in patients with infection-related versus non-infection-related AF (1st year 
from the index date: adjusted HR 1.40, 95% CI 1.13-1.74 for those on OAC therapy at the index 
date and adjusted HR 1.16, 95% CI 1.06-1.27 for those not on OAC therapy at the index date).  
Among patients with infection-related AF and available data on c-reactive protein level, 13.5% had 
a c-reactive protein level <10 mg/L, 32.1% from 10-49 mg/L, 54.4% >49 mg/L during their hospital 
admission. The risk of thromboembolic events in patients with infection-related AF and c-reactive 
protein >49 mg/L compared with patients with non-infection-related AF was: adjusted HR 1.25, 
95% CI 0.49-3.18 for those initiated on OAC therapy and adjusted HR 1.17, 95% CI 0.84-1.63 for 
those not initiated on OAC therapy during the 1st year of follow up. In the non-matched population, 
infection-related AF was associated with a higher risk of thromboembolic events compared with 
non-infection-related AF (1st year from the index date: adjusted HR 1.22, 95% CI 1.04-1.43 for 
those on OAC therapy at the index date and adjusted HR 1.14, 95% CI 1.05-1.24 for those not on 
OAC therapy at the index date).  
When dividing the group of patients with infection-related AF according to type of infection, 
pneumonia-related AF was associated with the highest risk of thromboembolic events. In general, 
the different subtypes of infection-related AF were associated with the same or an increased 
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thromboembolic risk as in patients with non-infection-related AF (Online Figure 2). Sub group 
analyses on different subgroups of the patients with infection-related AF according to underlying 
cardiac disease and AF risk factors showed similar results for the different groups with regard to 
thromboembolic events. 
 
Discussion 
We investigated long-term outcomes in patients with AF secondary to infection. The results 
indicated that infection-related AF is not as benign as previously considered. First, infection-related 
AF was associated with an increased risk of thromboembolic events during the 1st year of follow-
up and hereafter a comparable risk of thromboembolic events compared with non-infection-related 
AF. These findings were independent of OAC therapy status. Secondly, OAC therapy was 
associated with a lower risk of thromboembolic events and death compared with no OAC therapy 
for patients with infection-related AF as well as for patients with non-infection-related AF. Lastly, 
infection-related AF was associated with a lower risk of AF re-hospitalization than non-infection-
related AF.  
 
Thromboembolic risk and OAC therapy 
Infection-related AF vs. non-infection-related AF was associated with an increased thromboembolic 
risk during the 1
st
 year of follow up and a comparable thromboembolic risk thereafter. Further, 
different subtypes of infection-related AF (according to type of infection) were associated with the 
same or an even higher thromboembolic risk than in patients with non-infection-related AF. With 
regard to bleeding events, we observed no difference between patients with infection-related vs. 
non-infection-related AF among those initiated on OAC therapy. However, among those not 
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initiated on OAC therapy, infection-related AF was associated with an increased bleeding risk. This 
may indicate that this patient group represents a group of fragile patients.  
Previously, Lubitz et al. found no differences in the long-term risk of stroke among AF patients 
with and without a secondary precipitant. However, the number of patients investigated was low 
(439 patients with AF secondary to infection) compared with the study population in our study and 
the analyses were not stratified according to OAC therapy status.1 In 2014, Gialdini et al. found 
an association between perioperative AF and the long-term risk of ischemic strokes.19 Even 
though surgery is another secondary precipitant to AF than infection, this may reflect, that once AF 
has occurred, irrespective of the setting it occurs in, the patients carry an increased risk of 
thromboembolic events. Even though we cannot draw any causal link between infection-related AF 
and thromboembolic events, we suggest that infection-related AF and non-infection-related AF 
should be considered at least as equal with regard to thromboembolic risk.  
Despite adjustment for several potential confounders in our models, residual confounding cannot be 
excluded in our administrative registries. Until now, AF secondary to a reversible precipitant has 
been considered as a temporary event which terminates without recurrence, and therefore, the 
existence of un-identified confounders could be the explanation for the high long-term risk of 
thromboembolic events in patients with infection-related AF rather than AF itself. For example, the 
higher thromboembolic risk observed in patients with infection-related vs. non-infection-related AF 
during the 1
st
 year of follow up may be explained by a more active anticoagulation system in 
relation to the acute infection. However, OAC therapy in patients with infection-related AF was 
associated with the same reduction in thromboembolic risk and death as in non-infection-related 
AF. This may indicate that at least some of the high risk of thromboembolic events in the patients 
with infection-related AF were explained by AF. Moreover, the initiation rates of OAC therapy in 
patients with infection-related AF were markedly lower than for patients with non-infection-related 
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AF (24.3% vs. 41.7%). These results indicate the need for guidelines regarding OAC therapy for 
patients with AF secondary to a reversible precipitant, maybe on the same terms as for non-
infection-related AF. To support the findings of our study, data regarding AF secondary to other 
precipitants than infection are warranted.  
 
AF recurrence 
We found lower AF recurrence rates than those found in previous studies.1, 20 However, we 
studied re-hospitalizations and only included primary diagnoses of AF. This was done to avoid bias 
from the diagnosis coding. Therefore, AF as secondary diagnosis, outpatient hospital contacts with 
AF, and diagnoses from general practitioners were not included. This is likely to explain the lower 
recurrence rates in comparison with other studies. In the multivariable analysis, infection-related 
AF was associated with a significantly lower risk of AF rehospitalizations than non-infection-
related AF. This is in accordance with the findings by Lubitz et al. and Walkey et al. examining 
long-term outcomes in patients with first-detected AF and a secondary precipitant and patients with 
first-time AF during sepsis, respectively.1, 20 Siontis et al. recently found an increased risk of 
cerebrovascular events in patients with silent AF compared with patients with symptomatic AF.21 
Although speculative, it is possible that patients with infection-related AF had more silent episodes 
of AF not leading to hospitalization. This could explain why the patients with infection-related AF 
had lower AF re-hospitalization rates but at least as many thromboembolic events as the patients 
with non-infection-related AF.  
 
Limitations 
Our study had several limitations. Most importantly, it was a retrospective registry-based study. We 
looked at associations, and no causative relations can be drawn. No data on variables such as body 
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mass index, smoking habits, electrocardiograms, etc. were available. Moreover, the characterization 
of infection-related and non-infection-related AF was based on discharge diagnosis coding. To 
minimize the degree of misclassification bias, we restricted the group of patients with non-
infection-related AF to patients with AF as the primary diagnosis. Our results showed a notable 
difference in OAC initiation-rates among the two patient groups. This supports our succeeding in 
differentiating between patients with infection-related and non-infection-related AF. We had no 
access to patient files, and therefore, no data regarding physicians’ considerations with respect to 
the individual patient, the AF duration, and clinical presentation. This may have resulted in some 
degree of confounding by indication. Moreover, we did not know if the patients had sinus rhythm or 
AF at discharge. However, the proportion of patients in antiarrhythmic or rate-controlling therapy at 
the index date only differed slightly between the two patient groups. On the other hand, this study 
was based on nationwide registries from a tax-financed healthcare system with equal availability to 
health care services regardless of socioeconomic status. Further, these registries enabled long-term 
follow-up, an unselected study population, and available data on OAC therapy.  
 
Conclusion 
Infection-related AF was associated with at least as high thromboembolic risk as non-infection-
related AF. This was despite a lower recurrence rate of AF and the results were independent of 
OAC therapy status. Our results suggest that infection-related AF should be considered as at least 
equal to non-infection-related AF with regard to thromboembolic risk. Further, our results indicate 
that OAC therapy may be considered on the same terms for infection-related and non-infection-
related AF—something that currently is unclear in treatment guidelines.  
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Table 1: Baseline characteristics of the study population  
 Infection-related AF*  
N=24,322 
Non-infection-related AF* 
N=24,322 
Demographics + OAC
#
 
N=5981  
- OAC
#
 
N=18,341  
+ OAC
#
 
N=5981 
- OAC
#
 
N=18,341  
     
Age, median (IQR||) 77 (69-83) 79 (71-86) 77 (69-83) 79 (71-86) 
Female, no. (%) 2812 (47.0) 9943 (54.2) 2812 (47.0) 9943 (54.2) 
     
Comorbidities, no. (%)     
Alcohol abuse 201 (3.4) 1026 (5.6) 121 (2.0) 551 (3.0) 
Cancer 926 (15.5) 3947 (21.5) 852 (14.3) 3402 (18.6) 
Chronic kidney disease 350 (5.9) 1470 (8.0) 166 (2.8) 760 (4.1) 
Chronic obstructive pulmonary 
disease 
1227 (20.5) 3958 (21.6) 656 (11.0) 1952 (10.6) 
Diabetes 705 (11.8) 1753 (9.6) 508 (8.5) 1250 (6.8) 
Heart failure 1452 (24.3) 4502 (24.6) 1202 (20.1) 3093 (16.9) 
Hypertension 3819 (63.9) 8295 (45.2) 3975 (66.5) 8829 (48.1) 
Ischemic heart disease 1348 (22.5) 4852 (26.5) 1342 (22.4) 4511 (24.6) 
Liver disease 21 (0.4) 120 (0.7) 8 (0.1) 38 (0.2) 
Peripheral artery disease 349 (5.8) 1316 (7.2) 240 (4.0) 934 (5.1) 
Prior bleeding event 964 (16.1) 4013 (21.9) 825 (13.8) 3112 (17.0) 
Prior thromboembolic event 666 (11.1) 2306 (12.6) 541 (9.1) 1811 (9.9) 
Thyroid disease 369 (6.2) 1068 (5.8) 426 (7.1) 1119 (6.1) 
     
Risk scores     
CHA2DS2-VASc
‡ mean std¶ 3.4 (1.6) 3.4 (1.7) 3.3 (1.6) 3.2 (1.7) 
CHA2DS2-VASc
‡, median 
(IQR||) 
3 (2-4) 3 (2-5) 3 (2-4) 3 (2-4) 
CHADS2
†, mean std¶ 1.8 (1.2) 1.7 (1.2) 1.7 (1.1) 1.6 (1.2) 
CHADS2
†, median (IQR||) 2 (1-2) 2 (1-2) 2 (1-2) 1 (1-2) 
HAS-BLED§, mean std¶
 2.3 (1.1) 2.3 (1.2) 2.2 (1.1) 2.2 (1.1) 
HAS-BLED§, median (IQR||) 2 (1-3) 2 (1-2) 2 (1-3) 2 (1-3) 
     
Pharmacotherapy initiated during the blanking period, no. (%) 
Amiodarone 313 (5.2) 489 (2.7) 265 (4.4) 484 (2.6) 
Digoxin 3001 (50.2) 5773 (31.5) 2725 (45.6) 4902 (26.7) 
Dronedarone <5 <5 <5 <5 
Flecainide 10 (0.2) 31 (0.2) 22 (0.4) 139 (0.8) 
*AF: atrial fibrillation. 
†
CHADS2:
 
Risk score for stroke: congestive heart failure/LV function, hypertension, age>74 years, 
diabetes, stroke/TIA/systemic embolism (2 points). 
‡
CHA2DS2-VASc:
 
Risk score for stroke: congestive heart failure/LV 
function, hypertension, age 65-74 years, age>74 years (2 points), diabetes, stroke/TIA/ systemic embolism (2 points), 
vascular disease, sex category (female). 
§
HAS-BLED: Risk score for bleeding: hypertension, abnormal renal/liver function, 
history of stroke, history of bleeding, INR (left out due to missing data), age>65 years, drug consumption with antiplatelet 
agents/non-steroidal inflammatory drugs, alcohol abuse. 
||
Interquartile range.
 ¶
Standard deviation. 
#
Oral anticoagulation 
therapy status at the index date 
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Figure legends 
Figure 1: Patient selection. AF: atrial fibrillation. 
Figure 2: Cumulative incidence of thromboembolic events in AF patients with and without a 
concurrent infection according to OAC therapy status at the index date. (A: thromboembolic events, 
1st year since index date), B: thromboembolic events, one to five years since index date) and C: 
death, entire study period. AF: atrial fibrillation. OAC: oral anticoagulation. 
Figure 3: Incidence rates and adjusted HRs of long-term outcomes in patients with infection-related 
AF and non-infection-related AF according to OAC therapy status at the index date. AF: atrial 
fibrillation. CI: confidence interval. HR: hazard ratio. OAC: oral anticoagulation. 
Figure 4: Adjusted HRs of long-term outcomes in AF patients with and without a concurrent 
infection according to OAC therapy status at the index date. AF: atrial fibrillation. HR: hazard ratio. 
CI: confidence interval. OAC: oral anticoagulation. 
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Figure 1: Patient selection. AF: atrial fibrillation.  
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Figure 2: Cumulative incidence of thromboembolic events in AF patients with and 
without a concurrent infection according to OAC therapy status at the index date. (A: 
thromboembolic events, 1st year since index date), B: thromboembolic events, one to 
five years since index date) and C: death, entire study period. AF: atrial fibrillation. 
OAC: oral anticoagulation. 
A:   
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Figure 3: Incidence rates and adjusted HRs of long-term outcomes in patients with 
infection-related AF and non-infection-related AF according to OAC therapy status at 
the index date. AF: atrial fibrillation. CI: confidence interval. HR: hazard ratio. OAC: oral 
anticoagulation. 
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Figure 4: Adjusted HRs of long-term outcomes in AF patients with and without a 
concurrent infection according to OAC therapy status at the index date. AF: atrial 
fibrillation. HR: hazard ratio. CI: confidence interval. OAC: oral anticoagulation. 
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